Alirocumab

Revision as of 16:41, 10 November 2014 by Sergekorjian (talk | contribs)
Jump to navigation Jump to search
Pharmacologic interventions for PCSK9 Adapted from Journal of the American College of Cardiology, 62(16): 1401-1408[1]

For a review of all PCSK9 inhibitors please click here Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Properties

Major Trials

Phase II Trials

Phase III Trials

References

  1. Urban, D.; Pöss, J.; Böhm, M.; Laufs, U. (2013). "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis". J Am Coll Cardiol. 62 (16): 1401–8. doi:10.1016/j.jacc.2013.07.056. PMID 23973703. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources